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Glucagon-like peptide-1 (GLP-1) is a physiological regulator of appetite and long-acting GLP-1 
receptor agonists (GLP-1RA) lower food intake and bodyweight in both human and animal 
studies. The effects are mediated through brain GLP-1Rs, and several brain nuclei expressing the 
GLP-1R may be involved. To date, mapping the complete location of GLP-1R protein in the 
brain has been challenged by lack of good antibodies and the discrepancy between mRNA and 
protein especially relevant in neuronal axonal processes. Here, we present a novel and specific 
monoclonal GLP-1R antibody for immunohistochemistry with murine tissue and show detailed 
distribution of GLP-1R expression as well as mapping of GLP-1R mRNA by non-radioactive in 
situ hybridization. Semi-automated image analysis was performed to map the GLP-1R 
distribution to atlas plates from the Allen Institute of Brain Science (AIBS). The GLP-1R was 
abundantly expressed in numerous regions including the septal nucleus, the hypothalamus and 
the brain stem. GLP-1R protein expression was also observed on neuronal projections in brain 
regions devoid of any mRNA which has not been observed in earlier reports. Taken together, 
these findings provide new knowledge on GLP-1R expression in neuronal cell bodies and 
neuronal projections. 
GLP-1 is a neurotransmitter produced in the brain stem, and an incretin hormone released from 
gut endocrine L-cells. GLP-1 was shown to have a role in central regulating of feeding in rats 
and in humans GLP-1 activated brain areas known to regulate food intake. (1). GLP-1 also has 
an important role in regulating insulin release through activation of the GLP-1R expressed on 
pancreatic beta cells thereby lowering blood glucose levels (2). The GLP-1R is a Gs protein–
coupled receptor (GPCR) (3), and mRNA coding for the receptor is widely expressed in both 
rodents (4) and humans (5). Longer acting GLP-1RAs lower overall appetite (6) and bodyweight 
(7) through mechanisms in the brain (8, 9). In rodent models, GLP-1RAs also affect other central 
functions such as neuroprotection, learning and memory and has been shown to relieve 
symptoms in Alzheimer and Parkinson’s disease models (10). A complete characterization of the 
localization of GLP-1Rs throughout the brain will aid to delineate GLP-1R signaling in the brain 
potentially involved in these functions. Although extensive mapping of the receptor mRNA has 
previously been conducted (11), the mapping of GLP-1R protein distribution by 
immunohistochemistry (IHC) has been challenged by the lack of specific GLP-1R antibodies 
(12). Recently, the GLP-1R distribution in the brain was characterized by use of GLP-1R 
reporter mice (13). Albeit extensive, potential overestimation was emphasized due to the nature 
of the transgene being expressed at any time in development. Using the primate specific GLP-1R 
monoclonal antibody (MAb 3F52) (14) we have previously described the GLP-1R distribution in 
the non-human primate brain (15). Here, we present an additional specific monoclonal GLP-1R 
antibody (MAb 7F38A2) for the use with murine tissue and show the detailed distribution of 
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GLP-1R immunoreactivity in combination with a mapping of GLP-1R mRNA by non-
radioactive in situ hybridization (ISH). Both antibodies have been made available through the 
Developmental Studies Hybridoma Bank (Department of Biology, University of Iowa, Iowa 
City, IA).The GLP-1R distribution was mapped by image segmentation following semi-
automatic registration of the scanned histological slides to digital atlas plates from the AIBS 
mouse brain reference model (16, 17). IHC was performed on brain tissue derived from mice 
with a complete knock out of the GLP-1R (Glp-1r-/-) to further validate the antibody. 
Materials and Methods: 
Generation of anti-mouse GLP-1 receptor antibody 
   GLP-1R monoclonal antibody (7F38A2 3,6mg/ml) was generated at Novo Nordisk A/S. Glp-
1r-/- mice were immunized with baby hamster kidney (BHK) cells stably transfected with the 
mouse GLP-1R and antibodies were generated using standard hybridoma technology. The Glp-
1r-/- mice were on a C57BL background and were derived from the previously described Glp-1r-/- 
strain (18) custom bred by Novo Nordisk A/S at Taconic. The strain is not commercially 
available. GLP-1R specific antibodies were identified by image based screening (ImageXpress, 
Molecular Devices, CA) using the BHK-mouse GLP-1R (mGLP-1R) cells used for 
immunization and a mock transfected BHK cell-line for counter screen. Following isolation of 
the 7F38A2 clone and purification of the antibody, binding to mGLP-1R was validated in a flow 
cytometry experiment using transiently transfected HEK-mGLP-1R and HEK mock cells. 
Detection was done using an allophycocyanin-labelled anti-mouse antibody (#115-136-071, 
Jackson Immunoresearch, PA) diluted 1:500. The 7F38A2 antibody is a mouse IgG2aκ and anti-
TNP is an isotype control. For the immunostaining experiments the antibody was biotinylated 
using NHS-biotin (#H1759, Sigma) following the manufacturer’s instructions. 
The antibody is now available at http://dshb.biology.uiowa.edu/Mab-7F38?sc=9&category=-
109 
Animals 
   Male mice (C57BL/6J, and Glp1r-/-) and rats (Sprague Dawley) were obtained from Taconic, 
Denmark and housed 5 per cage in standard, temperature controlled conditions with a 12-hour 
light/dark cycle. The animals had ad libitum access to water and regular chow (no. 1324, 
Altromin, Brogaarden) unless otherwise stated. Handling and housing of the animals were 
conducted in accordance with approved national regulations in Denmark which are fully 
compliant with internationally accepted principles for the care and use of laboratory animals, and 
with animal experimental licenses granted by the Danish Ministry of Justice.   
Tissue preparation and sectioning 
   The animals were anesthetized with isoflurane and transcardially perfused with heparinized 
(10U/ml) saline (10 ml) followed by 10 % neutral buffered formalin (NBF) (10 ml). Brains were 
removed, immersed into 10 % NBF and stored at room temperature for 24 hours before being 
embedded into paraffin.  For whole brain receptor mapping one male mouse was used, and the 
entire brain was sectioned at 4.5 µm intervals and all sections were collected. Additionally, two 
male mice (one C57BL/6J, one Glp-1r-/-) and one male rat (Sprague Dawley) were used for a 
follow up study. Section thickness was 4.5 µm. 
Immunohistochemistry  
   For whole brain receptor mapping every 20th section was used for IHC. Paraffin sections were 
dewaxed and rehydrated in double distilled water. Sections were treated with 0.1 % pronase in 
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PBS at 37°C for 10 minutes and rinsed in Tris-buffered saline (TBS). Sections were then treated 
with 1 % H2O2 in TBS for 15 minutes, washed in TBS with 0.05 % Tween (TBS-T), blocked 
with avidin for 10 minutes (Dako, Glostrup, Denmark), washed with TBS-T, blocked with biotin 
for 10 minutes (Dako, Glostrup, Denmark), washed with TBS-T, and pre-incubated with 3.2 
mg/mL Poly L-Lysine, 3 % BSA bovine serum albumin, 7 % donkey serum and 3 % skimmed 
milk (Dako, Glostrup, Denmark) for 30 minutes. Sections were incubated overnight with primary 
biotinylated mouse GLP-1R antibody (MAb 7F38A2, Novo Nordisk, Måløv, Denmark) then 
washed three times for 10 minutes each in TBS-T, followed by treatment with Vectastain 
ABComplexHRP in TBS for 30 minutes and washed again three times for 10 minutes each. 
Sections were developed with diaminobenzidine (DAB+) (Dako, Glostrup, Denmark) and 
counterstained with hematoxylin, rinsed in water, dehydrated and mounted. Sections for the 
follow up study were stained with similar protocol with the exception of an additional Tyramide 
Signal Amplification (TSA) step and treatment with Vectastain ABComplexHRP, following 
primary antibody incubation which this time was reduced to two hours. All images were 
obtained using Hamamatsu NanoZoomer-XR. In addition, the staining protocol has been 
optimized for automatic staining applying the Ventana Discovery Ultra staining module. For 
details on this protocol please refer to the supplementary material. 
In situ hybridization  
   ISH was performed using the RNAscope platform (19, 20) on neighboring sections to the 
sections used for whole brain IHC mapping. The staining was performed using a Ventana 
Discovery XT system (Ventana MedicalSystems, Inc., Tucson, AZ) with RNAscope VS FFPE 
RED reagent kit (cat# 320610 from Advanced Cell Diagnostics, Hayward, CA). Briefly, the VS 
RNAscope protocol was used with the following pretreatment conditions: boiling for 2 minutes 
and pretreatment 2+3 steps for 4 minutes each with probes for bacterial DapB (negative control, 
cat. no. 310048), and mouse GLP-1R (cat. no. 415896). Images were obtained using Hamamatsu 
NanoZoomer-XR. 
To validate the signal obtained for GLP-1R mRNA, another mouse GLP-1R probe (no. 
415906) non-overlapping in sequence with probe no. 415896 was used on adjacent sagittal 
mouse brain sections. The signals obtained with both probes showed a complete overlap (data 
not shown). 
Image analysis and atlas plate generation 
   Image segmentation of the IHC and ISH slide scanner images were performed using a 
multinomial regression classifier trained on a constructed mosaic image for each staining type. 
The r,g,b values of the images were used as input features.  Prior to segmentation each IHC/ISH 
image pair was registered to a digital atlas plate obtained from the AIBS mouse brain reference 
model (16, 17). The specific atlas plates were manually selected from a collection of 528 plates. 
The image registration was performed in a coarse to fine manner with an affine transformation 
followed by non-linear b-spline transformation using sum of squared difference as similarity 
measure. All registrations were computed using Elastix (21). The final atlas plates were 
constructed by summing segmented signal inside a square mask moving across the registered 
images. A blue circle (IHC) or a red square (ISH) was drawn on the atlas plate if positive signal 
was detected. The diameter of the marker was based on the signal count applying a logarithmic 
scale to show both weak and strong signals. Following the automatic atlas plate generation 
manual corrections were performed in regions where the automatic image registration was not 
sufficiently accurate. 
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Results 
Antibody specificity 
   IHC staining with the GLP-1R antibody revealed high intensity staining with good resolution 
and low background (Figure 1). The antibody was specific for GLP-1Rs expressed in peripheral 
organs such as the Brunner’s gland (Figure 1, A-B) and further for mouse (Figure 1, C-F) and rat 
(Figure 1, G-H) brain. The expressional profile of GLP-1R was evaluated throughout the entire 
mouse brain, and this expression was confirmed in select regions in the rat brain in hypothalamus 
and brain stem showing correspondence between the two species in the regions investigated. 
However, some discrepancies existed between mouse and rat where GLP-1R expression could be 
observed in mouse lateral habenula, nucleus accumbens and in the nucleus of the lateral 
olfactory tract/cortical amygdalar area which was absent in rat brain (data not shown). Validation 
of the antibody has further been performed for GLP-1Rs in pancreas (22), kidney (23) and other 
peripheral GLP-1R expressing organs such as GI tract, lung and thyroid (data not shown).  
Distribution of GLP-1R  
Overall, GLP-1R protein and mRNA co-localized in most regions, however, some discrepancies 
was found such as in the posterior hippocampus, median eminence and terminal field of 
accessory olfactory bulb projections. The findings are summarized in Table 2 and on the atlas 
plate overlays (Figure 2, Figure 3). 
Telencephalon.  
In agreement with previous reports, GLP-1R protein positive cells were identified in the 
olfactory bulb, amygdala, dentate gyrus, septal nucleus, preoptic area, septofimbrial nucleus,  
triangular nucleus of septum, tenia tecta, vascular organ of the laminae terminalis, nucleus 
accumbens and bed nucleus of stria terminalis. Furthermore, protein was observed in the 
subfornical organ and in the terminal field of accessory olfactory bulb projections (the latter is 
included in the cortical amygdalar area in Table 2) where mRNA expression was absent (Table 
2). Especially in those regions where protein expression differed from mRNA expression, the 
specificity of the antibody was further validated by antibody staining on brain sections from Glp-
1r -/- mice. The data from the Glp-1r-/- mice showed complete absence of GLP-1R 
immunoreactivity, further establishing this antibody as specific towards the GLP-1R and 
confirming the presence of GLP-1R protein in these regions (Figure 4). 
Diencephalon.  
In the diencephalon GLP-1R protein and mRNA was observed in cells in zona incerta, tuberal 
nucleus, peripeduncular nucleus, and in hypothalamus in the arcuate nucleus, dorsomedial 
hypothalamic nucleus, lateral hypothalamic nucleus, paraventricular hypothalamic nucleus and 
supraoptic nucleus. Furthermore, GLP-1R protein was observed in median eminence as fibers 
only with no mRNA expression. The same pattern of presence of GLP-1R protein in the absence 
of mRNA expression was observed in the geniculate group of thalamus, posterior hypothalamic 
nucleus, habenula, and retrochiasmatic area (Table 2). When comparing mRNA expression 
reported by AIBS (http://www.brain-map.org/) with data obtained in the present study several 
areas expressing GLP-1R mRNA in the AIBS atlas were negative in the present study (Table 2). 
Mesencephalon.  
GLP-1R was observed in the anterior pretectal nucleus, medial and posterior pretectal area, the 
periaqueductal gray, and in the substantia nigra. GLP-1R protein was also observed in the motor 
related part of superior colliculus whereas mRNA expression could be observed in both the 
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motor related and the sensory related part of superior colliculus. Further discrepancies were 
observed in the dorsal raphe, the medial mammillary nucleus, the midbrain reticular nucleus and 
the ventral spinocerebellar tract where receptor was observed as protein on fibers only, lacking 
mRNA expression.   
Pons.  
In pons, GLP-1R protein and mRNA expression could be observed in the pontine grey, the 
parabrachial nucleus and the principal sensory nucleus of the trigeminal. Very few brain regions 
were positive for both protein and mRNA and only protein was observed in the nucleus incertus, 
nucleus of the lateral lemniscus, and the superior olivary complex whereas only mRNA was 
observed in the pontine reticular nucleus. 
Medulla.  
In Medulla, GLP-1R was observed in the area postrema, cuneate nucleus, inferior olivary 
complex, lateral reticular nucleus, nucleus tractus solitarus, medial vestibular nucleus, and the 
spinal nucleus of the trigeminal. GLP-1R protein but not mRNA was observed in the dorsal 
motor nucleus of the vagus nerve and in flocculus, residing in cerebellum, whereas mRNA was 
evident in nucleus ambiguus, and in the reticular nucleus. 
Discussion 
The reliable detection of the GLP-1R expression in tissues using IHC has been hampered by a 
lack of specific antibodies thus limiting well validated histological mapping studies to the 
detection of GLP-1R mRNA using ISH (12, 24, 25) and protein using in situ ligand binding with 
low spatial resolution (26). In this study an extensive mapping of GLP-1R mRNA and protein 
expression in the mouse brain is reported. For localization of GLP-1R protein a monoclonal 
GLP-1R antibody was used which is highly specific for murine GLP-1R as demonstrated by the 
complete absence of reactivity in mice lacking the GLP-1R. The localization of GLP-1R protein 
was combined with detection of GLP-1R mRNA on adjacent sections using non-radioactive ISH, 
enabling a higher accuracy for anatomical localization compared to a radioactivity based 
approach. The expression patterns observed showed good alignment between protein and mRNA 
expression but also revealed some regions only positive for GLP-1R protein and encompassing 
axonal projections. This is a well described phenomenon in the brain where protein and gene 
expression do not always correlate (27, 28, 29), possibly in situations where protein can be 
transported away from the nuclear processing site along the axonal processes. This phenomenon 
necessitates caution when interpreting potential GLP-1 interacting brain regions and neurons 
based on receptor mRNA expression alone, as such data will underestimate the number of GLP-1 
binding sites. The distribution of GLP-1R protein in the mouse brain has previously been 
described using a transgene Glp-1r reporter mouse (13). When comparing GLP-1R protein 
expression detected using the antibody in the present study with the study by Cork et al (13) 
there is a high level of agreement with a few exceptions where some positive regions were seen 
using IHC but not reported by Cork et al. Of note, several of these regions were regions lacking 
mRNA expression, indicating the presence of protein exclusively on projections and terminals. 
Thus, IHC seems an easier approach to obtain high sensitivity for GLP-1R expression including 
axonal processes, without requiring generation of reporter mice. Interestingly, the concern for 
artefactual overexpression of GLP-1R in the Glp-1r reporter mouse as a result of accumulated 
gene transcription during embryogenesis does not seem to be a problem in the case of the GLP-
1R, as all regions reported positive in the reporter mouse were also seen with antibody staining.  
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Comparing mRNA expression in the present study to that reported by AIBS revealed several 
areas where mRNA was reported to be present by AIBS (e.g. nucleus of the trapezoid body, 
septohippocampal nucleus, dorsal peduncular area, and tegmental reticular nucleus) but not 
observed in our study (and hence not included in Table 2). These inconsistencies are likely due 
to a higher specificity of the RNAscope ISH platform used here as demonstrated by the full 
overlap of signals obtained with two non-overlapping probes for GLP-1R. Another explanation 
could be the more extensive sampling of the mouse brain in studies reported by AIBS potentially 
revealing sub nuclei with limited GLP-1R expression that was not picked up in this study. 
To verify that the antibody could also be applied to rat tissue, select sections from rat brain 
were stained and examined. Although there was a good agreement with respect to localization of 
the GLP-1R between mouse and rat on sections with hypothalamus and brain stem, it must be 
emphasized that the entire rat brain was not analyzed and a discrepancy between mouse and rat 
in GLP-1R localization in the brain was detected in some regions. In general more GLP-1R 
protein was observed in the mouse brain compared to the rat brain. A large part of the additional 
GLP-1R protein was seen in mouse axonal processes such as in medial habenula and cortical 
amygdalar area which were absent in the rat. Thus, to fully characterize the GLP-1R in rat brain 
a full mapping is needed rather than assuming complete correspondence between species. 
Considering the relative small fraction of neurons in the hindbrain that produce GLP-1, a 
remarkable abundance of GLP-1Rs were found to be expressed throughout the brain indicating 
potential diverse actions of this neurotransmitter. Indeed, central GLP-1 activity has been 
reported to affect functions such as feeding behavior, body weight and temperature, malaise, 
fluid homeostasis, stress response, and learning and memory (30, 31). One of the most abundant 
GLP-1R populations was found in the caudal division of the lateral septal nucleus a population 
that is little understood with respect to GLP-1 actions. The caudal part of lateral septal nucleus 
has been characterized as abundant in somatostatin neurons which has been shown to act 
inhibitory in septal nucleus (32, 33). Further building on this inhibitory mechanism, other studies 
have suggested that GLP-1R expressing neurons in LS are GABA’ergic and connected to GLP-1 
actions on behaviors associated with reward (34, 35). Septal projections are extensive and 
include innervation of hypothalamus, supramammilary nucleus, hippocampus, thalamus, and 
ventral tegmental area (36). Thus the involvement in reward signaling may only be a one GLP-1 
mediated behavior initialized from this area.  
Another area with high expression of GLP-1R positive fibers was in the dentate gyrus which 
is the principal input to the rest of the hippocampus forming the “tri-synaptic hippocampal 
circuit” associated with episodic memory consolidation and formation (37). The dentate gyrus is 
capable of generating new granule cells in the adult brain (38, 39), which has been linked to 
memory formation and maintenance as well as neuroprotection (40, 41). Hence, GLP-1R 
expression in this area could be coupled to some of the beneficial effects reported with GLP-1 
regulation of memory and Alzheimer’s disease (42) and neuroprotection (31). 
A high expression of GLP-1R was also identified on fibers projecting to the median 
eminence. The median eminence is usually associated with the integration of the hypothalamic 
pituitary axis serving as an area of release from paraventricular hypothalamic neurons to the 
bloodstream. On top of this, literature suggests the median eminence to be a site for uptake of 
peripheral peptides such as leptin and ghrelin from the blood (43, 44) through receptor specific 
uptake; this could be extended to include GLP-1RAs. Indeed all circumventricular organs 
including the median eminence have a high expression of GLP-1R suggesting interaction with 
peripheral GLP-1 in these regions.  
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In summary, we report here a full mapping of GLP-1R protein and mRNA in the mouse brain 
using IHC with a specific monoclonal antibody and ISH, respectively. The strength of using a 
fully validated and specific antibody is emphasized by the ability to detect GLP-1R protein in 
regions devoid of mRNA and in neuronal projections where it was not observed using a 
transgenic reporter system.  
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Figure 1. GLP-1R IHC with antibody Mab 7F38A2 on paraffin-embedded mouse Brunner’s 
Gland (A–B) and mouse brain (C-F). B, High magnification of the solid-line box in A. E and F, 
Magnifications of solid-line boxed areas in C and D, respectively. C and E are from a Glp-1r-/- 
mouse while D and F are from a C57BL/6J mouse. GLP-1R IHC with antibody Mab 7F38A2 on 
paraffin-embedded rat brain (G–H). G, High magnification image of the hypothalamus showing 
positive staining in arcuate hypothalamic nucleus and median eminence. H, High magnification 
image showing positive staining in area postrema, dorsal motor nucleus of the vagus nerve and 
nucleus of the solitary tract. Scale bar in A corresponds to 2000 um. Scale bar in B corresponds 
to 100 um. Scale bar in C-D corresponds to 2000 um. Scale bar in E-F corresponds to 250 um. 
Scale bar in G corresponds to 500 um. Scale bar in H corresponds to 500 um. 
Figure 2. Atlas plates (bregma 2.86 to -1.70) showing distribution of signals for mouse GLP-1R 
ISH (red squares) and GLP-1R IHC (blue circles). The distribution is overlaid onto digital atlas 
plates constructed from the AIBS mouse brain atlas. The distribution of GLP-1R mRNA and 
protein are indicated on the left half of the atlas plates and brain regions with positive staining 
for either GLP-1R mRNA or protein are highlighted with a solid color on the right half of the 
atlas plates.  Brain region abbreviations follow the nomenclature of the AIBS mouse brain 
reference atlas which can be found at: http://atlas.brain-map.org/ 
Figure 3. Atlas plates (bregma -3.16 to -7.32) showing distribution of signals for mouse GLP-1R 
ISH (red squares) and GLP-1R IHC (blue circles). The distribution is overlaid onto digital atlas 
plates constructed from the AIBS mouse brain atlas. The distribution of GLP-1R mRNA and 
protein are indicated on the left half of the atlas plates and brain regions with positive staining 
for either GLP-1R mRNA or protein are highlighted with a solid color on the right half of the 
atlas plates.  Brain region abbreviations follow the nomenclature of the AIBS mouse brain 
reference atlas which can be found at: http://atlas.brain-map.org/ 
Figure 4. High magnification images of adjacent sections of C57BL/6J mouse brain tissue 
focusing on terminal field of accessory olfactory bulb projections (A-B). A, Mouse GLP-1R ISH 
showing lack of signal. B, GLP-1R IHC with antibody Mab 7F38A2 showing positive staining. 
C, GLP-1R IHC with antibody Mab 7F38A2 on a corresponding section from a Glp1r-/- mouse 
brain showing negative staining. Scale bars correspond to 400 um. 
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Table 1. Antibody Table 
Peptide/Protein Target Name of antibody Manufacturer, Catalog #, 
and/or Name of Individual 
Providing the Antibody 
Species Raised in; 
Monoclonal or 
Polyclonal 
Dilution 
Used 
RRID 
GLP-1R MAb 7F38A2 Developmental Studies 
Hybridoma Bank, Mab 7F38 
Mouse, 
Monoclonal 
1:720 AB_2618101 
Table 2. Summary of GLP-1R (IHC and ISH) location in C57BL/6J mouse brain and comparison 
to external references 
Structure Area Protein mRNA Cork et al (13) (protein) AIBS (mRNA) 
Telencephalon AOB Accessory olfactory bulb + + + + 
BMA Basomedial amygdalar nucleus + - + + 
CeA Central amygdala + + + + 
CeA/AAA Central amygdala/Anterior 
amygdalar area 
+ + + + 
COA Cortical amygdalar area + - + + 
DG Dentate gurys + + + + 
LPO Lateral preoptic area + + + + 
LS Lateral septal nucleus + + + + 
NLOT/COA Nucleus of the lateral olfactory 
tract/Cortical amygdalar area 
+ - + + 
PA Posterior amygdalar nucleus + - + + 
SF Septofimbrial nucleus + + NA + 
SFO Subfornical organ + + + + 
TRS Triangular nucleus of septum - + NA + 
TT Tenia tecta + + + + 
OV Vascular organ of the laminae 
terminalis 
+ NA + NA 
ACB Nucleus accumbens + + + + 
BST Bed nucleus of stria terminalis + + + + 
Diencephalon ARH Arcuate hypothalamic nucleus + + + + 
DMH Dorsomedial hypothalamic nucleus + + + + 
GENd Geniculate group, dorsal thalamus + - + + 
Hb Habenula  + - + + 
LHA Lateral hypothalamic nucleus + + + + 
ME Median eminence + - NA + 
PH Posterior hypothalamic nucleus + - + + 
PP Peripeduncular nucleus + + NA + 
PVH Paraventricular hypothalamic 
nucleus 
+ + + + 
RCH Retrochiasmatic area + - + + 
SO Supraoptic nucleus + + NA + 
TU Tuberal nucleus + + NA + 
ZI Zona incerta + + + + 
Mesencephalon APN Anterior pretectal nucleus + + + + 
DR Dorsal raphe + - NA + 
MM Medial mammillary nucleus + - + + 
MPT Medial pretectal area + + + + 
MRN Midbrain reticular nucleus + - NA + 
PAG Periaqueductal gray + + + + 
PPT Posterior pretectal area + + + + 
SCs Superior colliculus, sensory related - + NA + 
SCm Superior colliculus, motor related + + NA + 
SCTV ventral spinocerebellar tract + - NA + 
SNr Substantia nigra, reticular part + + NA + 
SNc Substantia nigra, compact part + + NA + 
Pons NI Nucleus incertus + - NA + 
NLL Nucleus of the lateral lemniscus + - NA + 
PB Parabrachial nucleus + + NA + 
PCG Pontine central gray + - NA + 
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PG Pontine gray + + NA + 
PRNc Pontine reticular nucleus, caudal 
part 
- + NA + 
PRNr Pontine reticular nucleus - + NA + 
PSV Principal sensory nucleus of the 
trigeminal 
+ + NA + 
SOC Superior olivary complex + - NA + 
Medulla AMB Nucleus ambiguus - + NA + 
AP Area postrema + + + + 
CU Cuneate nucleus + + NA + 
DMX Dorsal motor nucleus of the vagus 
nerve 
+ - NA + 
ECU External cuneate nucleus + + NA + 
FL  Flocculus (cerebellum) + - NA + 
IO Inferior olivary complex + + + + 
LRNm Lateral reticular nucleus, 
magnocellular part 
+ + NA + 
MARN Magnocellular reticular nucleus - + NA + 
MDRN Medullary reticular nucleus - + NA + 
MV Medial vestibular nucleus + + NA + 
NTS Nucleus tractus solitarus + + + + 
PARN Parvicellular reticular nucleus - + NA + 
SPVC Spinal nucleus of the trigeminal, 
caudal part 
+ + NA + 
Presence (+) or absence (-) of GLP-1R protein and mRNA in mouse brain. The two right columns indicate whether 
GLP-1R was observed as protein (Cork et al) or mRNA (AIBS). NA: not assessed/reported. 
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